Tekmira provides periodic update to shareholders regarding litigation


Tekmira Pharmaceuticals provided a periodic update to its shareholders on the ongoing litigation with Alnylam Pharmaceuticals (AMLN) and AlCana Technologies. CEO Dr. Mark J. Murray commented: "We are firmly committed to regaining control of our LNP technology and preserve its full value for Tekmira. The Massachusetts Superior Court has issued a pre-trial scheduling order with the timeline for the remaining pre-trial events leading up to a trial commencing on Nov. 14, 2012."

View Comments (0)